Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Ancient Retrovirus Embedded in the Human Genome Helps Fight HIV-1 Infection

By Kumamoto University | June 27, 2017

HERV-K Gag and HIV-1 Gag coassembly cause a reduction in both HIV-1 particle release and infectivity.

Throughout our evolution, viruses have continually infected humans just as they do today. Some early viruses became integrated into our genome and are now known as human endogenous retroviruses (HERVs). Over millions of years, they became inert due to mutations or major deletions in their genetic code. Today, one of the most studied HERV families is the HERV-K family, which has been active since the evolutionary split of humans and chimpanzees with some members perhaps actively infecting humans within the past couple hundred thousand years.

HERVs have become a target for HIV researchers because studies have shown that T-cells produce an immune response against HERVs in those infected with HIV. It is now thought that HERV expression can be caused by HIV infection and that HIV would become an easier target by aiming at the HERV antigens rather than the ever-mutating HIV antigens. Following that idea, previous research from Kumamoto University in Japan revealed an apparent correlation between the coassembly of HIV-1 group specific antigen (Gag) and HERV-K Gag, and the reduced particle proliferation and infectivity of HIV-1. In their current study, the researchers sought to clarify how HERV-K Gag affects HIV-1 in this manner.

They reported that HERV-K Gag changes the size and morphology of progeny HIV-1 particles during the early stages of coassembly. This occurs because the HERV-K Gag capsid (CA), i.e. the virus protein shell, colocalizes (overlaps) partially with HIV-1 Gag at the plasma membrane. This also results in a reduced number of mature HIV-1 particles and lower HIV-1 release and infectivity.

“While we have found that release efficiency and infectivity of HIV-1 particles are hindered by HERV-K Gag,” said project leader, Dr. Kazuaki Monde, “they appear to be products of two separate mechanisms. HIV-1 particle release from cells that also express HERV-K Gag is reduced significantly but the specifics of how infectivity is also reduced still eludes us. Certainly, more research into HERV-K CA is needed to determine how it is able to reduce both particle release and infectivity of HIV-1.”

[Reference]

Monde, K.; Terasawa, H.; Nakano, Y.; Soheilian, F.; Nagashima, K.; Maeda, Y. & Ono, A., Molecular mechanisms by which HERV-K Gag interferes with HIV-1 Gag assembly and particle infectivity, Retrovirology, Springer Nature, 2017. 
DOI: 10.1186/s12977-017-0351-8


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
A media release and Scientific Report image of Elizabeth Kellogg. - Camera Settings: ILCE-9M2, 12mm, ISO 1000, 1/80, f/3.2, Fri, 04-19-2024 at 10:10. v.12.01.23
St. Jude pioneers gene editing and structural biology to advance pediatric research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE